Sergott covers the Healthcare sector, focusing on stocks such as Pacific Biosciences, Charles River Labs, and Quest Diagnostics. Icon has an analyst consensus of Strong Buy, with a price target ...

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Siegfried Holding AG (SGFEF – Research Report) and Icon ...

Since the 1960s, people have been searching for the mythical creature known as Bigfoot. Most cryptozoologists would place him ...

New York State Common Retirement Fund raised its holdings in shares of Pacific Biosciences of California, Inc. (NASDAQ:PACB – ...

Pacific Biosciences of California (PACB) came out with a quarterly loss of $0.20 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.27 per share a year ago.

In the last three months, 4 analysts have published ratings on Pacific Biosciences (NASDAQ:PACB), offering a diverse range of perspectives from bullish to bearish. In the table below, you'll find ...

Pacific Biosciences of California (PACB) ended the recent trading session at $1.22, demonstrating a +1.67% swing from the preceding day's closing price. The stock's change was less than the S&P 500's ...

For the quarter ended December 2024, Pacific Biosciences of California (PACB) reported revenue of $39.22 million, down 32.8% over the same period last year. EPS came in at -$0.20, compared to -$0. ...

MENLO PARK, Calif. (AP) — MENLO PARK, Calif. (AP) — Pacific Biosciences of California Inc. (PACB) on Thursday reported fourth-quarter profit of $3.6 million. The Menlo Park, California-based ...